Monday, December 16, 2019 3:14:56 PM
My views:
Bad luck last Friday with the slip and the freeze and then after-hours run up when if it were all handled like we have seen these things happen over the years the news should have broke more records.
But we all know this now.
What we all happened to forget was the shorts needed an exit and low and behold the criminal like stock market did their usual and stopped the climb in order to stop their bleeding.
But for so much volume we are holding up exceptionally which is a testament to our greatness. Maybe not happening today but tomorrow and then on we should get our just reward.
Last week Thero was a hero by most here, today a goat by some here. I have heard that many times. What are the odds of us having a genius (which he is) and a phenomenal personality (which we all know he doesn't). Come on, better a genius than a great public speaker with minimal depth. Yeah I know we could have done the interview(s) 10x better, but that doesn't matter, those are temporary swings. AMRN has the goods, now all we need is time and a great BO offer and we will be on our way, just a matter of time. I wish crystal balls were sold at Walmart.
Bad luck last Friday with the slip and the freeze and then after-hours run up when if it were all handled like we have seen these things happen over the years the news should have broke more records.
But we all know this now.
What we all happened to forget was the shorts needed an exit and low and behold the criminal like stock market did their usual and stopped the climb in order to stop their bleeding.
But for so much volume we are holding up exceptionally which is a testament to our greatness. Maybe not happening today but tomorrow and then on we should get our just reward.
Last week Thero was a hero by most here, today a goat by some here. I have heard that many times. What are the odds of us having a genius (which he is) and a phenomenal personality (which we all know he doesn't). Come on, better a genius than a great public speaker with minimal depth. Yeah I know we could have done the interview(s) 10x better, but that doesn't matter, those are temporary swings. AMRN has the goods, now all we need is time and a great BO offer and we will be on our way, just a matter of time. I wish crystal balls were sold at Walmart.
Recent AMRN News
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
